Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note released on Monday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Down 0.2 %

Shares of EGRX stock opened at $6.03 on Monday. The business’s fifty day simple moving average is $4.45 and its 200-day simple moving average is $4.97. Eagle Pharmaceuticals has a 12-month low of $3.21 and a 12-month high of $23.52. The company has a market cap of $78.33 million, a PE ratio of 5.11 and a beta of 0.51.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD acquired a new position in shares of Eagle Pharmaceuticals in the 1st quarter valued at $83,000. Vanguard Group Inc. boosted its holdings in Eagle Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after purchasing an additional 2,630 shares during the last quarter. Headlands Technologies LLC boosted its holdings in Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 2,861 shares during the last quarter. DGS Capital Management LLC boosted its holdings in Eagle Pharmaceuticals by 442.5% in the first quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock valued at $325,000 after purchasing an additional 50,525 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its holdings in Eagle Pharmaceuticals by 110.1% in the first quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock valued at $1,005,000 after purchasing an additional 100,470 shares during the last quarter. 85.36% of the stock is owned by institutional investors and hedge funds.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.